Breaking News, Financial News

Financial Report: Cambrex Corp. 4Q

Sales in the quarter were up 1% excluding the impact of foreign exchange. Sales of controlled substances increased due to higher demand, offset by decreases due to delays in certain custom development projects, lower sales of generic APIs, and lower contr

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cambrex Corp. 4Q Revenues: $65.2 million (-7%) 4Q Loss: $697,000 (earnings were $265,000 4Q07) FY Revenues: $249.6 million (-1%) FY Earnings: $8.2 million (earnings were $209.2 million FY07) Comments: Sales in the quarter were up 1% excluding the impact of foreign exchange. Sales of controlled substances increased due to higher demand, offset by decreases due to delays in certain custom development projects, lower sales of generic APIs, and lower contractual pricing of a gastro-in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters